Patents by Inventor David B. MacLean

David B. MacLean has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of prostate cancer
    Patent number: 11583526
    Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: February 21, 2023
    Assignees: Myovant Sciences GmbH, Takeda Pharmaceutical Company Limited
    Inventors: Vijaykumar Reddy Rajasekhar, Brendan Mark Johnson, David B. MacLean, Lynn Seely, Paul N. Mudd, Jr.
  • TREATMENT OF PROSTATE CANCER
    Publication number: 20220401443
    Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 15, 2022
    Publication date: December 22, 2022
    Inventors: Vijaykumar Reddy RAJASEKHAR, Brendan Mark JOHNSON, David B. MACLEAN, Lynn SEELY, Paul N. MUDD, JR.
  • TREATMENT OF PROSTATE CANCER
    Publication number: 20210205303
    Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 20, 2020
    Publication date: July 8, 2021
    Inventors: Vijaykumar Reddy RAJASEKHAR, Brendan Mark JOHNSON, David B. MacLEAN, Lynn SEELY, Paul N. MUDD, JR.
  • Treatment of prostate cancer
    Patent number: 10786501
    Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: September 29, 2020
    Assignees: Myovant Sciences GmbH, Takeda Pharmaceutical Company Limited
    Inventors: Vijaykumar Reddy Rajasekhar, Brendan Mark Johnson, David B. MacLean, Lynn Seely, Paul N. Mudd, Jr.
  • TREATMENT OF PROSTATE CANCER
    Publication number: 20200129507
    Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 6, 2019
    Publication date: April 30, 2020
    Inventors: Vijaykumar Reddy RAJASEKHAR, Brendan Mark JOHNSON, David B. MacLEAN, Lynn SEELY, Paul N. MUDD, JR.
  • Treatment of prostate cancer
    Patent number: 10449191
    Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: October 22, 2019
    Assignees: Myovant Sciences GmbH, Takeda Pharmaceutical Company Limited
    Inventors: Vijaykumar Reddy Rajasekhar, Brendan Mark Johnson, David B. MacLean, Lynn Seely, Paul N. Mudd, Jr.
  • TREATMENT OF PROSTATE CANCER
    Publication number: 20190224196
    Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 25, 2019
    Inventors: Vijaykumar Reddy RAJASEKHAR, Brendan Mark JOHNSON, David B. MacLEAN, Lynn SEELY, Paul N. MUDD, Jr.
  • Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
    Patent number: 6911456
    Abstract: The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I wherein the variables A, B, Y, D, Z1, G and e are as described herein.
    Type: Grant
    Filed: April 26, 2002
    Date of Patent: June 28, 2005
    Assignee: Pfizer Inc
    Inventors: David B. MacLean, David D. Thompson
  • Use of growth hormone secretagogues for treatment of physical performance decline
    Publication number: 20040122062
    Abstract: This invention is directed to methods for treating age-related decline in physical performance which comprises administering a growth hormone secretagogue, a prodrug thereof or a pharmaceutically acceptable salt of said secretagogue or said prodrug.
    Type: Application
    Filed: November 24, 2003
    Publication date: June 24, 2004
    Applicant: Pfizer Inc
    Inventors: David B. MacLean, William H. Landschulz
  • Use of estrogen antagonists and estrogen agonists inhibiting pathological conditions
    Publication number: 20040009994
    Abstract: The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I 1
    Type: Application
    Filed: July 7, 2003
    Publication date: January 15, 2004
    Applicant: Pfizer Inc.
    Inventors: David B. MacLean, David D. Thompson
  • Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
    Publication number: 20030220349
    Abstract: The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I 1
    Type: Application
    Filed: April 26, 2002
    Publication date: November 27, 2003
    Inventors: David B. MacLean, David D. Thompson
  • Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
    Patent number: 6613796
    Abstract: The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I
    Type: Grant
    Filed: November 15, 2001
    Date of Patent: September 2, 2003
    Assignee: Pfizer Inc.
    Inventors: David B. Maclean, David D. Thompson
  • Therapy for andropause using estrogen agonists / antagonists and testosterone
    Publication number: 20020115676
    Abstract: The present invention concerns the treatment of andropause and related conditions using a combination of an estrogen agonist/antagonist and testosterone.
    Type: Application
    Filed: November 27, 2001
    Publication date: August 22, 2002
    Inventor: David B. MacLean
  • Intermittent administration of a growth hormone secretagogue
    Publication number: 20020094992
    Abstract: The present invention relates to the intermittent administration of a growth hormone secretagogue to a patient.
    Type: Application
    Filed: August 27, 2001
    Publication date: July 18, 2002
    Inventor: David B. MacLean
  • Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
    Publication number: 20020091121
    Abstract: The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I 1
    Type: Application
    Filed: November 15, 2001
    Publication date: July 11, 2002
    Inventors: David B. MacLean, David D. Thompson
  • Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
    Patent number: 6403611
    Abstract: The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: June 11, 2002
    Assignee: Pfizer Inc.
    Inventors: David B. Maclean, David D. Thompson
  • Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
    Patent number: 6355670
    Abstract: The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I
    Type: Grant
    Filed: February 23, 2000
    Date of Patent: March 12, 2002
    Assignee: Pfizer, Inc.
    Inventors: David B. Maclean, David D. Thompson
  • Use of growth hormone secretagogues for treatment of physical performance decline
    Publication number: 20020028838
    Abstract: This invention is directed to methods for treating age-related decline in physical performance which comprises administering a growth hormone secretagogue, a prodrug thereof or a pharmaceutically acceptable salt of said secretagogue or said prodrug.
    Type: Application
    Filed: June 27, 2001
    Publication date: March 7, 2002
    Inventors: David B. MacLean, William H. Landschulz
  • Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
    Publication number: 20010018451
    Abstract: The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I 1
    Type: Application
    Filed: March 9, 2001
    Publication date: August 30, 2001
    Inventors: David B. Maclean, David D. Thompson
  • Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
    Patent number: 6274618
    Abstract: The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I
    Type: Grant
    Filed: May 19, 1999
    Date of Patent: August 14, 2001
    Assignee: Pfizer Inc
    Inventors: David B. MacLean, David D. Thompson